Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EYEG Stock Forecast 2025-2026
$35.30
Current Price
$161.51M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EYEG Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
EYEG Price Momentum
-0.6%
1 Week Change
+1.2%
1 Month Change
0.0%
1 Year Change
+0.9%
Year-to-Date Change
-5.2%
From 52W High of $37.24
+4.1%
From 52W Low of $33.92
📊 TOP ANALYST CALLS
Did EYEG Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if EyeGate is one of their latest high-conviction picks.
Latest EYEG Stock Price Targets & Analyst Predictions
Comprehensive analyst forecasts are currently unavailable for EYEG. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYEG Analyst Ratings
3
Buy
0
Hold
0
Sell
EYEG Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $35.30
Latest EYEG Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYEG.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 16, 2021 | HC Wainwright & Co. | Yi Chen | Buy | Maintains | $11.00 |
| Nov 12, 2020 | HC Wainwright & Co. | Buy | Maintains | $0.00 | |
| Jul 21, 2020 | Alliance Global Partners | Buy | Initiates | $0.00 | |
| May 19, 2020 | HC Wainwright & Co. | Buy | Reiterates | $0.00 | |
| Nov 15, 2017 | H.C. Wainwright | Buy | Maintains | $0.00 | |
| Apr 7, 2016 | Noble Financial | Buy | Initiates | $0.00 |
EyeGate Pharmaceuticals Inc (EYEG) Competitors
The following stocks are similar to EyeGate based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EyeGate Pharmaceuticals Inc (EYEG) Financial Data
EyeGate Pharmaceuticals Inc has a market capitalization of $161.51M with a P/E ratio of -19.9x. The company generates $12,059 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of N/A and return on equity of +7.5%.
Valuation Metrics
Market Cap
$161.51M
Enterprise Value
$160.69M
P/E Ratio
-19.9x
PEG Ratio
1.0x
Price/Sales
13,393.5x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
EPS Growth
N/A
Financial Health
Cash/Price Ratio
0.0%
Current Ratio
20.2x
Debt/Equity
0.0x
ROE
+7.5%
ROA
-577.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
EyeGate Pharmaceuticals Inc (EYEG) Business Model
About EyeGate Pharmaceuticals Inc
What They Do
Invests in investment-grade fixed-income securities.
Business Model
The fund generates revenue by investing a minimum of 80% of its net assets in investment-grade fixed-income securities issued by corporate entities. Its strategy focuses on securities that may have connections to government interests, enhancing stability and potential returns.
Additional Information
This investment approach aims to provide investors with a steady income stream while managing risk through the selection of high-quality corporate bonds.
EyeGate Pharmaceuticals Inc (EYEG) Latest News & Analysis
Latest News
Bonds still bouncing along
9 months ago
Quick Summary
Bond prices remain volatile, indicating fluctuations in the bond market. Investors should monitor these trends for potential impacts on investment strategies.
Why It Matters
Fluctuations in bond prices indicate market volatility and investor sentiment, which can impact interest rates, borrowing costs, and overall economic conditions.
Source: CNBC Television
Market Sentiment:
Neutral
AllianceBernstein Launches 5 New Active ETFs
1 year ago
Quick Summary
AllianceBernstein has launched five active ETFs, including two on the NYSE and three on Nasdaq, after surpassing $1 billion in active ETF AUM.
Why It Matters
AllianceBernstein's launch of five active ETFs indicates growth in their offerings and market confidence, potentially attracting more investments and impacting the competitive landscape.
Source: ETF Trends
Market Sentiment:
Positive
Quick Summary
AllianceBernstein has expanded its ETF suite with one Buffered product and four Fixed Income products, announced on December 13, 2023, in Nashville, Tennessee.
Why It Matters
The introduction of new ETF products by AllianceBernstein may attract investor interest, potentially increasing assets under management and impacting market liquidity and investment strategies.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
EyeGate Pharmaceuticals has incorporated Bayon Therapeutics' vision-restoring small molecules into its development pipeline, expanding its product offerings.
Why It Matters
EyeGate's acquisition of Bayon Therapeutics' vision-restoring molecules expands its product pipeline, potentially enhancing growth prospects and attracting investor interest in the biotech sector.
Source: GlobeNewsWire
Market Sentiment:
Neutral
EYEG Stock Price: Why It Substantially Increased
3 years ago
Quick Summary
Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) saw a 22.95% increase in its stock price during the previous trading session.
Why It Matters
Eyegate Pharmaceuticals' significant stock price increase signals strong investor interest or positive news, potentially indicating future growth or market confidence.
Source: Pulse2
Market Sentiment:
Positive
Quick Summary
Seven penny stocks listed on Nasdaq are noted for their potential safety when balanced with risk in investment portfolios.
Why It Matters
Penny stocks with Nasdaq listings may offer higher growth potential with relatively more stability, attracting risk-tolerant investors seeking diversification and upside opportunities.
Source: InvestorPlace
Market Sentiment:
Positive
Frequently Asked Questions About EYEG Stock
What is EyeGate Pharmaceuticals Inc's (EYEG) stock forecast for 2026?
Analyst forecasts for EyeGate Pharmaceuticals Inc (EYEG) are not currently available. The stock is trading at $35.30.
Is EYEG stock a good investment in 2026?
According to current analyst ratings, EYEG has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $35.30. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EYEG stock?
Price predictions from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.30.
What is EyeGate Pharmaceuticals Inc's business model?
The fund generates revenue by investing a minimum of 80% of its net assets in investment-grade fixed-income securities issued by corporate entities. Its strategy focuses on securities that may have connections to government interests, enhancing stability and potential returns.
What is the highest forecasted price for EYEG EyeGate Pharmaceuticals Inc?
Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.30.
What is the lowest forecasted price for EYEG EyeGate Pharmaceuticals Inc?
Price targets from Wall Street analysts for EYEG are not currently available. The stock is trading at $35.30.
What is the overall EYEG consensus from analysts for EyeGate Pharmaceuticals Inc?
The overall analyst consensus for EYEG is bullish. Out of 2 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell.
How accurate are EYEG stock price projections?
Stock price projections, including those for EyeGate Pharmaceuticals Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 6:05 AM UTC